A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Cirrhosis associated with metabolic associated fatty liver disease (MAFLD) can lead to a series of adverse outcomes in and outside the liver, but there is no approved treatment so far. In recent years, the prevalence of MAFLD-related cirrhosis in our country is increasing rapidly, but its clinical, pathological characteristics and natural prognosis are not clear, and there is a lack of standardized and effective prevention and treatment strategies.ThroughDigital Intelligence software to assist clinicians in MAFLD patients with remote data intervention, lifestyle intervention guidance and follow-up management, to evaluate the efficacy and safety of the intervention software on body weight and blood glucose in patients with MAFLD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Adult patients aged 18-65 years with a BMI of 24-35 kg/m².

• Confirmed diagnosis of Metabolic-associated Fatty Liver Disease (MAFLD), defined by a FibroScan® result \> 248 dB/m or an MRI-PDFF \> 5%.

• Willing and able to provide written informed consent and comply with the study protocol, including the use of a compatible smartphone for digital health components.

• If treated for Type 2 Diabetes Mellitus (T2DM), must be on a stable medication regimen for at least 3 months prior to baseline (Day 0), with the expectation to maintain stability throughout the study barring medical necessity.

• If taking medications with potential NASH-remitting effects (e.g., vitamin E, thiazolidinediones), must be on a stable dose for at least 3 months prior to Day 0.

Locations
Other Locations
China
Hangzhou Normal University Hospital
RECRUITING
Hangzhou
Contact Information
Primary
junping shi, doctor's degree
20131004@hznu.edu.cn
+86 139 5712 1199
Time Frame
Start Date: 2024-08-01
Estimated Completion Date: 2028-08-30
Participants
Target number of participants: 2000
Treatments
No_intervention: Life intervention group
Detailed nutritional intervention protocols were developed according to patients' food preferences, dietary habits, physical activity levels, working conditions, sociocultural conditions, and lifestyle. Low-carbon diet and balanced diet were adopted for dietary intervention. According to the patients' basic metabolic level, overweight and fatty liver degree, a calorie restriction diet was formulated, and it was recommended to reduce 500-1000 kcal calories per day, a balanced diet of pastries and carbohydrates, with increased intake of whole grains, omega-3 fatty acid, and dietary fiber. Choose the right ingredients for your particular patient's diet
Placebo_comparator: Digital Intelligence Software Group
Study participants were guided by the program officer to download and register theData Intelligence software (patient-side) and to establish a relationship with the clinicians involved in the study, baseline data were collected under the guidance of the program director, health records were created, and data were collected using a software-supportedBody composition analyzer.. The participating clinicians evaluated the subjects through theDigital Intelligence software (doctor side), and formulated the diet and exercise program according to the individual conditions of the subjects.
Related Therapeutic Areas
Sponsors
Leads: The Affiliated Hospital of Hangzhou Normal University

This content was sourced from clinicaltrials.gov